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ARTICLE
A high-throughput screen identifies that CDK7
activates glucose consumption in lung cancer cells
Chiara Ghezzi1,2, Alicia Wong1,2, Bao Ying Chen1,2, Bernard Ribalet3, Robert Damoiseaux1,2,4 &
Peter M. Clark 1,2,4,5*
Elevated glucose consumption is fundamental to cancer, but selectively targeting this path-
way is challenging. We develop a high-throughput assay for measuring glucose consumption
and use it to screen non-small-cell lung cancer cell lines against bioactive small molecules.
We identify Milciclib that blocks glucose consumption in H460 and H1975, but not in
HCC827 or A549 cells, by decreasing SLC2A1 (GLUT1) mRNA and protein levels and by
inhibiting glucose transport. Milciclib blocks glucose consumption by targeting cyclin-
dependent kinase 7 (CDK7) similar to other CDK7 inhibitors including THZ1 and LDC4297.
Enhanced PIK3CA signaling leads to CDK7 phosphorylation, which promotes RNA Poly-
merase II phosphorylation and transcription. Milciclib, THZ1, and LDC4297 lead to a
reduction in RNA Polymerase II phosphorylation on the SLC2A1 promoter. These data indi-
cate that our high-throughput assay can identify compounds that regulate glucose con-
sumption and that CDK7 is a key regulator of glucose consumption in cells with an activated
PI3K pathway.
https://doi.org/10.1038/s41467-019-13334-8 OPEN
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E levated tumor glucose consumption, also known as theWarburg effect, is fundamental to most cancers1–3. TheWarburg effect is induced by oncogenes or by the loss of
tumor suppressors, and is exploited clinically to visualize cancer
with 18F-2-fluoro-2-deoxyglucose (18F-FDG) PET4–10. Targeting
glucose consumption in cancer alone or in combination with
other therapies can limit cancer cell growth and induce apopto-
sis11–16. Glucose consumption in cancer is primarily targeted
using 2-deoxyglucose (2-DG), a glucose analog that at high
concentrations can function as a prodrug and can target
the hexokinase enzymes that catabolize glucose11–16. However, 2-
DG is poorly selective for cancer over non-transformed cells,
leading to significant on-target toxicities in patients and limiting
the use of 2-DG clinically17. Inhibitors that target the GLUT
glucose transporters show promise but have yet to be tested in
patients18,19.
Cancer cells, despite using the same biochemical enzymes as
non-transformed cells to consume glucose, use different signaling
pathways to regulate these enzymes20–22. Targeting these path-
ways may represent a strategy to block cancer cell glucose con-
sumption while sparing healthy cells and may provide greater
selectivity than directly targeting the enzymes that metabolize
glucose. However, such an approach will require a deeper
understanding of the pathways that regulate glucose consumption
in cancer and new ways to target these pathways.
A major challenge of studying glucose consumption has been
the lack of high-throughput methods for measuring this pathway.
Standard assays use isotopically labeled glucose or glucose analogs
(i.e. 13C-glucose, 3H-2-DG, 18F-FDG) or quantify changes in
media glucose consumption and are low-throughput21,23. High-
throughput assays, coupled to small molecule or genetic libraries,
are a powerful method for identifying new regulators of a protein
or pathway24,25.
Here, we adapted and optimized a luminescence-based glucose
consumption assay into a high-throughput assay with the
necessary properties for use in a high-throughput screen. We
screened 3555 compounds against A549, H460, and HCC827
non-small-cell lung cancer (NSCLC) cells and identified 97
inhibitors of glucose consumption including the small molecule
Milciclib. Milciclib inhibits glucose transport by blocking CDK7
from phosphorylating and activating RNA Polymerase II down-
stream of activated PIK3CA.
Results
A high-throughput assay for measuring glucose consumption.
Glucose consumption is usually evaluated by measuring the
accumulation of long-lived radio-labeled or stable isotope-labeled
glucose analogs into cells21,23, methods that would be challenging
to implement in a high-throughput assay. Luminescence is a
preferred readout for high-throughput screens, and a recent study
described a luminescence-based assay for measuring cellular
glucose consumption26,27. This assay measures 2-DG-6-
phosphate levels using a coupled enzyme assay in cells treated
with 2-DG27 (Supplementary Fig. 1). We tested the sensitivity of
this assay to drug-induced changes in glucose consumption and
compared these results to results obtained using 3H-2-DG.
Cytochalasin B is a small molecule inhibitor of the GLUT glucose
transporters28. The luminescence-based glucose consumption
assay measured a 79.1 ± 0.7% (mean ± standard error of the mean
(SEM)) decrease in glucose consumption in Cytochalasin B-
treated cells, which was similar to the 76.8 ± 1.5% decrease in
glucose consumption measured using 3H-2-DG (Fig. 1a), con-
sistent with previous studies27. Both PI3K and EGFR activate
glucose consumption in cancer9,22. Using the luminescence-based
glucose consumption assay, we identified that the PI3K inhibitor
Buparlisib and the EGFR inhibitor Erlotinib blocked glucose
consumption by 82.4 ± 3.0% and 40.7 ± 9.7%, respectively. Similar
results were obtained using 3H-2-DG (a 74.9 ± 3.0% and 49.3 ±
2.0% decrease with Buparlisib and Erlotinib, respectively; Fig. 1a).
These data indicate that the luminescence-based glucose con-
sumption assay can sensitively and accurately measure drug-
induced changes in glucose consumption.
Converting this low-throughput, luminescence-based glucose
consumption assay into a miniaturized, high-throughput assay
required a number of significant modifications. Potential
liabilities included wash steps to remove endogenous glucose,
which could lead to variable cell loss, and consecutive reagent
addition steps, which could compound liquid handling errors.
Simply applying this assay as described in the literature27 to an
automated, high-throughput workflow with volumes scaled
proportionate to the surface area of wells in a 384-well
plate produced an assay with a Z-factor of −1.59 ± 0.29 with
Cytochalasin B as the positive control. However, multiple rounds
of optimization yielded a robust protocol: cells expressing a
nuclear-localized blue-fluorescent protein (BFP+ cells) are plated
into wells of a 384-well plate containing small molecules or
DMSO in media. Following a 24 h incubation, the cells are
quickly washed with 1x PBS containing 0.25% BSA, and 2-DG is
added. Over a 20 min period in which the cells are incubated with
the 2-DG, an automated fluorescent microscope images and
counts the BFP+ cells in each well. A stop buffer is added
followed by a neutralization and detection reagent, and the
luminescence is measured on a plate reader (Fig. 1b). Results are
reported as luminescence per BFP+ cell. Key features of this
protocol include the fluorescent imaging step, which removed any
variability in the luminescence output caused by differential cell
loss during the washes; the addition of BSA to the wash solutions
to decrease surface tension, which increased assay reproducibility;
and an optimized ratio of stop buffer to neutralization and
detection reagent, which maximized output while minimizing
background signal. Across three-cell lines, the assay yielded a Z-
factor of 0.75 ± 0.02 and 0.59 ± 0.05 using no 2-DG and
Cytochalasin B as the positive controls, respectively (Fig. 1c).
These results suggest that our high-throughput assay has the
necessary properties for incorporation into a high-throughput
screen.
Discovering inhibitors of glucose consumption in NSCLC cells.
NSCLC cells have elevated glucose consumption, and inhibiting
glucose consumption in these cells limits their growth and sen-
sitizes them to chemotherapy11,13,29. We screened A549, H460,
and HCC827 NSCLC cells against 3555 bioactive small molecules
from four small molecule libraries: the Selleck Chemicals kinase
inhibitor library, the Prestwick FDA-approved drug library, the
LOPAC collection, and the NIH clinical collection. A549 cells
carry a G12S KRAS mutation, H460 cells carry a Q61H KRAS
and E545K PIK3CA mutations, and HCC827 cells carry an EGFR
Exon 19 deletion30. This screen yielded a list of small molecules
and their effects on glucose consumption in each cell line (Fig. 2a:
waterfall plots; Fig. 2b: example heat map). While most of the
compounds had little effect on glucose consumption, a small
number of compounds altered cellular glucose consumption. Our
high-throughput assay has a standard deviation of 7.6% (Fig. 1c),
so we chose a 50% decrease in glucose consumption (e.g.
>6 standard deviations from the mean) as our cut-off for evalu-
ating potential hits. Using this cut-off, we identified 34, 95, and 66
putative inhibitors of glucose consumption in A549, H460, and
HCC827 cells, respectively. 8, 61, and 44 of these putative inhi-
bitors were validated in A549, H460, and HCC827 cells, respec-
tively, following a secondary screen. This yielded a reconfirmation
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rate of 58% and provided a list of validated inhibitors of glucose
consumption in these cell lines (Supplementary Table 1). Only 16
of these small molecules overlap across two cell lines, potentially
suggesting that these genetically distinct cell lines use different
mechanisms to promote glucose consumption.
Our list of validated hits includes known and novel inhibitors
of glucose consumption including kinase inhibitors (Lapatinib,
Dovitinib, and Gefitinib), topoisomerase inhibitors (Ellipticine
and (S)-(+)-camptothecin), and dopamine receptor agonists (R-
(−)-propylnorapomorphine and L-apomorphine) (Supplemen-
tary Table 1). Approximately 30% of the validated hits are
profiled in the Connectivity Map31. Consistent with their shared
ability to limit glucose consumption, the inhibitors we identified
link to overexpression of UGCG and SLC37A4, two genes whose
protein products consume or sequester metabolites of glucose
(Fig. 2c). Additionally, knockdown or inhibition of various
proteins involved in receptor tyrosine kinase signaling are
connected to the inhibitors we identified (Fig. 2c, Supplementary
Fig. 2), consistent with a role for receptor tyrosine kinases in
driving glucose consumption in cancer21,22. We cannot readily
explain other connected genetic alterations including knockdown
of COPA, TERF1, and CHMP2A, and overexpression of FIS1, but
these insights could form the basis for future studies. The only
overlap between these results and connections identified from a
control set of compounds was ERBB3 knockdown.
We further analyzed 14 of our validated hits by determining
glucose consumption IC50 values. Based on the results of our
high-throughput screen, Reserpine does not affect glucose
consumption in A549 cells, so we used it as a negative control.
IC50 values could be determined for all of the compounds except
for our negative control (Fig. 2d). In these targeted analyses and
in the high-throughput screens, there was no consistent
connection between whether, 24 h post-drug treatment, a small
molecule inhibitor blocked glucose consumption and whether
that same inhibitor blocked cell growth although specific
examples of this connection do exist (Supplementary Fig. 3).
Collectively, these data indicate that our high-throughput assay
can be used to identify small molecule inhibitors of glucose
consumption. The results of this screen are a list of known and
novel inhibitors of glucose consumption in NSCLC (Supplemen-
tary Table 1).
Milciclib inhibits glucose consumption in H460 cells. Milciclib
is an inhibitor of CDK2, CDK4, CDK7, and TRKA32,33 and in our
high-throughput screen we found that it blocks glucose con-
sumption specifically in H460 cells. This suggests a potential
mechanistic connection between cell cycle regulation and meta-
bolism in NSCLC through a cyclin-dependent kinase and that
Milciclib may block glucose consumption downstream of a spe-
cific genetic alteration and thus show specificity for some cancers
over healthy cells. We further evaluated whether Milciclib blocked
H460 cell glucose consumption in cell culture and in vivo using
additional and orthogonal assays. Consistent with the results of
our high-throughput assay, 10 µM Milciclib decreased glucose
consumption in H460 cells by 65.8 ± 3.1% and 42.7 ± 6.2% as
evaluated by measuring 3H-2-DG consumption or media glucose
levels, respectively (Fig. 3a, b). Cancer cells catabolize glucose to
lactate8. Milciclib decreased H460 lactate production by 48.7 ±
10.6% (Fig. 3b). Milciclib blocked glucose consumption in H460
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Fig. 1 A high-throughput assay for measuring glucose consumption. a Glucose consumption in H460 (top and middle) and HCC827 (bottom) cells treated
with Cytochalasin B (10 μM), Buparlisib (1 μM), Erlotinib (200 nM), or vehicle, measured by a luminescence-based 2-DG or a 3H-2-DG consumption assay.
n= 3. P values determined by a two-way ANOVA test. b Schematic workflow of a luminescence-based high-throughput assay for measuring glucose
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(10 μM), or without 2-DG. n= 16. Data are plotted as mean ± SEM.
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Fig. 2 A high-throughput screen identifies inhibitors of NSCLC glucose consumption. a Waterfall plots of glucose consumption in A549, H460, and
HCC827 cells treated with one of 3555 small molecule inhibitors. n= 1. b Example heat map of glucose consumption from a 384-well plate of H460 cells
treated with small molecules from the NIH clinical collection. c Genetic alterations connected to the small molecules we identified as inhibitors of glucose
consumption. Analysis performed using the Connectivity Map. OE overexpression, KD knockdown. d Glucose consumption dose response curves and
values for a subset of the compounds identified in the high-throughput screen. Reserpine in A549 cells is used as a negative control. n= 3 per
concentration except n= 2 for H460 cells treated with Reserpine.
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but not in A549 or HCC827 cells even though Milciclib-inhibited
cell growth in all three cell lines (Fig. 3c). Milciclib blocked glu-
cose consumption in H460 cells after 16 h but before 24 h of
treatment (Fig. 3d). In vivo, Milciclib blocked glucose con-
sumption in H460 cell xenografts by 30.4 ± 2.5%, as assessed
using 18F-FDG PET imaging, without affecting glucose con-
sumption in the mouse brain, heart, liver, or muscle (Fig. 3e,
Supplementary Fig. 4). This suggests that Milciclib may inhibit
glucose consumption selectively in cancer. Vehicle treatment did
not significantly affect H460 cell xenograft glucose consumption
(6.0 ± 6.0% increase) (Fig. 3e). Collectively, these data provide
strong evidence that Milciclib inhibits glucose consumption
selectively in H460 cells in cell culture and in vivo.
Milciclib blocks GLUT expression and glucose transport.
Cancer cells predominantly express SLC2A1 (GLUT1) and SLC2A3
(GLUT3) to transport glucose across the cell membrane and Hex-
okinase 1 and Hexokinase 2 to phosphorylate glucose34,35. GLUT1,
GLUT3, and Hexokinase 2 mRNA levels were lower in H460 cells
treated with Milciclib compared to vehicle-treated cells (GLUT1,
GLUT3, and Hexokinase 2 mRNA levels after 20 h: 76.9 ± 5.5%,
42.5 ± 7.7%, and 67.8 ± 3.4% of control values, respectively; GLUT1,
GLUT3, and Hexokinase 2 mRNA levels after 24 h: 70.6 ± 4.9%,
64.5 ± 13.1%, and 47.2 ± 5.8% of control values, respectively;
Fig. 4a). Hexokinase 1 mRNA levels were higher at 20 h and lower
at 24 h post-Milciclib treatment compared to vehicle-treated cells
(20 h: 121.1 ± 4.5% of control values; 24 h: 71.1 ± 7.1% of control
values; Fig. 4a). Milciclib decreased GLUT1, GLUT3, Hexokinase 1,
and Hexokinase 2 protein levels in H460 cells to 49.6 ± 6.1%, 84.3 ±
2.6%, 93.5 ± 3.9%, and 85.3 ± 6.3% of control values, respectively
(Fig. 4b; Supplementary Fig. 5). In A549 and HCC827 cells, Mil-
ciclib had no significant effect on or slightly increased GLUT1,
GLUT3, Hexokinase 1, or Hexokinase 2 protein levels (Supple-
mentary Fig. 6). We further analyzed the effect of Milciclib on
glucose transport and hexokinase activity in H460 cells using a
FRET-based glucose reporter36,37. The rate of change in the FRET
ratio following removal of glucose alone measures the combined
activity of the glucose transporters and the hexokinases38. The rate
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of change in the FRET ratio following removal of glucose in the
presence of Cytochalasin B measures exclusively the hexokinase
activity. Milciclib did not significantly affect the rate of change of
the FRET ratio following removal of glucose in the presence of
Cytochalasin B (t1/2= 110.9 ± 14.6 and 101.5 ± 9.2 s for vehicle and
Milciclib, respectively; Fig. 4c), suggesting that Milciclib does not
affect hexokinase activity. However, Milciclib significantly decreased
the rate of change of the FRET ratio following removal of glucose
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without Cytochalasin B treatment (t1/2= 11.5 ± 1.0 and 32.1 ± 3.8 s
for vehicle and Milciclib, respectively; Fig. 4c), suggesting that
Milciclib limits glucose consumption by decreasing the rate of
glucose transport.
If Milciclib blocks glucose consumption by decreasing GLUT
transporter levels, then overexpression of GLUT1 or
GLUT3 should rescue this effect. H460 cells that overexpress
GLUT1, GLUT3, or YFP were treated with vehicle or Milciclib,
and glucose consumption was measured 24 h post-drug treat-
ment. GLUT1 and GLUT3 overexpression increased GLUT1 and
GLUT3 protein levels compared to YFP overexpression (Fig. 4d).
GLUT1 and GLUT3 overexpression also shifted the Milciclib
glucose consumption IC50 value by over 10-fold compared to cells
overexpressing YFP without significantly affecting how much
Milciclib alters cell growth 24 h post-Milciclib treatment (normal-
ized cell numbers of YFP, GLUT1, and GLUT3 overexpression
cells treated with Milciclib: 69.4 ± 3.4, 62.8 ± 3.9, and 60.7 ± 3.8,
respectively; Fig. 4e). Additionally, GLUT1 overexpression
decreased the ability of Milciclib to inhibit cell growth at 48 h
post-drug treatment (Fig. 4f). This may suggest that part of the
mechanism through which Milciclib blocks cell growth is by
decreasing glucose consumption although additional experiments
will be required to fully evaluate this possibility. Collectively our
data suggest that Milciclib decreases glucose consumption in
H460 cells by downregulating GLUT1 and GLUT3 mRNA and
protein levels, thereby limiting glucose transport.
Milciclib limits glucose consumption by inhibiting CDK7.
Known targets of Milciclib include CDK2, CDK4, CDK7, and
TRKA32,33. We transfected H460 cells with a control shRNA or
pooled shRNA targeting CDK2, CDK4, CDK7, or TRKA, which
decreased the expression of their respective protein targets by
34.4 ± 2.7%, 44.8 ± 4.6%, 42.3 ± 0.9%, and 43.5 ± 2.8% compared
to the control shRNA (Fig. 5a). Knockdown of CDK7 and TRKA
significantly decreased glucose consumption to 68.5 ± 1.1% and
81.8 ± 3.3% of control values, respectively, while knockdown of
CDK2 and CDK4 had no significant effect on glucose con-
sumption (102.1 ± 3.0% and 102.7 ± 6.3% of control values,
respectively; Fig. 5b). To further evaluate these results, H460 cells
were transfected with a control shRNA or with individual shRNA
targeting CDK7 or TRKA. Both constructs decreased the
expression of their respective protein target (CDK7: 45.6 ± 1.3%
decrease, TRKA: 42.1 ± 7.2% decrease; Fig. 5a), but only the
shRNA targeting CDK7 significantly decreased cellular glucose
consumption to 54.2 ± 6.3% of control values (Fig. 5c). CDK7
knockdown in H460 cells also decreased the ability of Milciclib to
inhibit glucose consumption and cell growth (normalized cell
numbers of H460 cells transfected with a control shRNA, pooled
CDK7 shRNA, or individual CDK7 shRNA and treated with
Milciclib: 63.5 ± 1.6, 71.8 ± 1.8, and 87.4 ± 3.9, respectively;
Fig. 5d; Supplementary Fig. 7). CDK7 siRNA transfected into
H460 cells decreased CDK7 protein levels by 52.8 ± 1.8% and
yielded similar results (Supplementary Fig. 8). CDK7 knockdown
in H460 cells significantly decreased GLUT1 but not GLUT3
mRNA and protein levels suggesting that CDK7 regulates GLUT1
mRNA and protein levels (Fig. 5e, f, Supplementary Fig. 8;
GLUT1 mRNA levels: 31.9 ± 4.3% decrease, GLUT1 protein
levels: 61.9 ± 5.8% decrease, averaged across both shRNA
sequences). CDK2 and CDK4 knockdown did not significantly
affect GLUT1 proteins levels but TRKA knockdown decreased
GLUT1 protein levels by 13 ± 1.5%, averaged across both shRNA
sequences (Supplementary Fig. 9). These data indicate that CDK7
knockdown and Milciclib treatment both inhibit glucose con-
sumption and that CDK7 and Milciclib regulate glucose con-
sumption through the same pathway. Combined with studies
showing that Milciclib directly inhibits CDK7 (ref. 32), this data
suggests that Milciclib blocks glucose consumption in H460 cells
by inhibiting CDK7. Given the variable protein knockdown
efficiencies and the potential that different proteins require dif-
ferent levels of depletion before a phenotypic effect can be
observed, we cannot conclude from this data whether other
known or unknown Milciclib targets also regulate glucose
consumption.
Despite repeated attempts, the knockdown efficiency of CDK7
we were able to achieve in H460 cells was moderate, possibly due
to the essential nature of this protein for cancer and other
dividing cell populations39,40. The same studies suggest that
CDK7 knockout cells would be unlikely to grow. To provide
further evidence that CDK7 regulates glucose consumption in
H460 cells, we tested two additional CDK7 inhibitors. THZ1
inhibits CDK7 with additional activity against CDK12 (ref. 41).
LDC4297 inhibits CDK7 with additional activity against CDK2
and CDK5 (ref. 42). Notably, although Milciclib, THZ1, and
LDC4297 all have additional targets beyond CDK7, none of these
additional targets are shared between all three inhibitors. Both
THZ1 and LDC4297 decreased glucose consumption in H460 but
not A549 or HCC827 cells despite blocking cell growth in all
three cell lines (Supplementary Fig. 10a). CDK7 knockdown in
H460 cells reduced the ability of THZ1 and LDC4297 to block
glucose consumption, suggesting that THZ1 and LDC4297
decrease glucose consumption by inhibiting CDK7 (Supplemen-
tary Fig. 10b, c). Consistent with a mechanism in which CDK7
inhibition blocks glucose transport, THZ1 significantly decreased
GLUT1 mRNA and protein levels by 42.9 ± 4.4% and 40.7 ± 1.3%,
respectively (Supplementary Fig. 11). LDC4297 significantly
decreased GLUT1 mRNA and protein levels by 71.7 ± 8.3% and
39.2 ± 2.4%, respectively (Supplementary Fig. 11). Milciclib,
THZ1, and LDC4297 did not decrease GLUT1 mRNA levels in
HCC827 cells (Supplementary Fig. 12). Overall this data provides
additional evidence that CDK7 regulates the expression of
GLUT1 mRNA and protein levels.
CDK7 may promote HIF1α transcriptional activity in chronic
lymphocytic leukemia cell lines, and the expression of GLUT1,
GLUT3, Hexokinase 1, and Hexokinase 2 is regulated by
HIF1α43,44. Our experiments were conducted at atmospheric
oxygen concentrations, and HIF1α protein levels are undetectable
in H460 cells and were not induced by Milciclib (Supplementary
Fig. 13a). Additionally, Milciclib had no consistent effect on
HIF1α-regulated gene products, repressing the expression of
GLUT1, GLUT3, Hexokinase 1, Hexokinase 2, and Ceruloplas-
min, while having no effect on the expression of SERPINE1 and
inducing the expression of VEGFA (Fig. 4a and Supplementary
Fig. 13b). These data provide evidence that Milciclib does not
repress GLUT1, GLUT3, Hexokinase 1, and Hexokinase 2 mRNA
levels through HIF1α regulation.
PI3K signaling promotes glucose consumption through CDK7.
CDK7 is a CDK-activating kinase (CAK), and as a subunit of the
transcription factor TFIIH, it promotes various steps in tran-
scription by phosphorylating Ser5 in the C-terminal domain
(CTD) of the Rpb1 subunit of RNA polymerase II45–47. Since
Milciclib, THZ1, and LDC4297 decrease GLUT1 mRNA levels
(Fig. 4a; Supplementary Fig. 11), we focused on a potential
mechanism through which CDK7 regulates GLUT1 transcription.
Studies suggest that phosphorylation of CDK7 at Thr170 can
stabilize the TFIIH complex and selectively activate the CTD
kinase activity of CDK7, and that the PI3K pathway may regulate
phosphorylation at this site47,48. H460 cells have an activating
E545K mutation in the catalytic PI3K subunit PIK3CA30. H460
cells are the only cell line among the three that we studied with a
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genetic alteration in the PI3K pathway30 and the only cell line in
which Milciclib, THZ1, and LDC4297 block glucose consumption
(Fig. 3c, Supplementary Fig. 10a), suggesting a potential role for
the PI3K-signaling pathway in regulating glucose consumption
through CDK7. Neither Milciclib, THZ1, nor LDC4297 inhibit
glucose consumption in HCC827 cells (Fig. 3c, Supplementary
Fig. 10a). However overexpression of wild-type PIK3CA in
HCC827 cells increased phospho-AKT levels by 244 ± 30%,
increased phospho-CDK7 levels by 48.3 ± 3.7%, increased GLUT1
levels by 85.0 ± 0.1%, and sensitized HCC827 cells to the
inhibitory effect of Milciclib, THZ1, and LDC4297 on glucose
consumption without significantly affecting how much Milciclib
inhibits cell growth (normalized cell numbers of control and
PIK3CA overexpressing HCC827 cells treated with Milciclib:
66.1 ± 1.6% and 72.1 ± 2.4%, respectively; Fig. 6a, b, Supplemen-
tary Fig. 14). The phosphatase and tensin homolog (PTEN)
protein opposes the activity of PIK3CA49. Overexpression of
PTEN in H460 cells decreased phospho-AKT levels by 55.5 ±
5.8%, decreased phospho-CDK7 levels by 38.7 ± 4.8%, decreased
GLUT1 levels by 16.0 ± 1%, and blocked the inhibition of glucose
consumption by Milciclib, THZ1, and LDC4297 without
significantly affecting how much Milciclib inhibits cell growth
(normalized cell numbers of control and PTEN-overexpressing
H460 cells treated with Milciclib: 70.4 ± 4.1% and 69.9 ± 4.1%,
respectively; Fig. 6c, d, Supplementary Fig. 15a). Glucose
consumption in HCC827 cells is not sensitive to Milciclib
(Fig. 3c) and overexpression of PTEN in HCC827 cells had no
significant effect on the ability of Milciclib to inhibit glucose
consumption despite decreasing phospho-AKT levels by 61.9 ±
5.9% (Supplementary Fig. 15b, c).
To further test our finding that aberrant PIK3CA activity
promotes glucose consumption through CDK7, we evaluated
H1975 cells, which have an activating G118D mutation in
PIK3CA30. Similar to H460 cells (Fig. 3c, Supplementary Fig. 10a),
Milciclib, THZ1, and LDC4297 reduced glucose consumption
and cell growth in H1975 cells (Fig. 6e, Supplementary Fig. 16a).
Individual or pooled shRNA constructs targeting CDK7
decreased CDK7 protein levels by 43.7 ± 0.2% and 41.1 ± 6.2%,
GLUT1 mRNA levels by 43.1 ± 1.1% and 24.6 ± 0.9%, GLUT1
protein levels by 51.7 ± 2.7% and 46.0 ± 12.6%, and glucose
consumption by 34.6 ± 4.1% and 35.3 ± 5.9%, respectively, and
blocked Milciclib, THZ1, and LDC4297 from inhibiting glucose
consumption in H1975 cells (Fig. 6e, Supplementary Fig. 16).
Individual and pooled shRNA constructs targeting CDK7 also
blocked Milciclib from inhibiting cell growth in H1975 cells
(normalized cell numbers of H1975 cells transfected with a
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control shRNA, an individual CDK7 shRNA, or a pooled
CDK7 shRNA and treated with Milciclib: 61.0 ± 5.0%, 96.3 ±
4.4%, and 86.1 ± 6.9%, respectively). CDK7 siRNA decreased
CDK7 protein levels by 75 ± 8% in H1975 cells and yielded
similar results (Supplementary Fig. 17). Milciclib, THZ1, and
LDC4297 also significantly decreased GLUT1 mRNA and protein
levels in H1975 cells (Supplementary Fig. 18). Consistent with a
role for mutant PIK3CA in regulating glucose consumption
through CDK7 in H1975 cells, overexpression of PTEN in these
cells decreased phospho-AKT levels by 27.4 ± 1.6%, decreased
phospho-CDK7 levels by 34.4 ± 1.5%, decreased GLUT1 levels by
46.5 ± 10.9%, and desensitized the cells to the inhibitory effects of
Milciclib, THZ1, and LDC4297 on glucose consumption without
significantly affecting how much Milciclib inhibits cell growth
(normalized cell numbers of control or PTEN-overexpressing
H1975 cells treated with Milciclib: 64.5 ± 4.5% and 66.3 ± 1.8%,
respectively; Fig. 6f, g, Supplementary Fig. 19). These data fit a
model in which mutant activated PIK3CA promotes enhanced
glucose consumption in NSCLC cancer cells in part through the
activation of CDK7. However, insofar as PI3K signaling regulates
many different proteins and pathways50, we cannot rule out
pleiotropic effects of PIK3CA or PTEN overexpression that may
contribute to our results. For example, one protein known to
regulate glucose consumption downstream of PI3K signaling is
thioredoxin interacting protein (TXNIP)51–54. Although we do
not identify significant changes in TXNIP protein levels in
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HCC827 cells that overexpress PIK3CA, in H460 cells that
overexpress PTEN, and in H460 cells treated with Milciclib
(Supplementary Fig. 20), we cannot rule out a role for TXNIP in
our system.
PKCι activates CDK7 to promote glucose consumption. PKCι
phosphorylates Thr170 on CDK7 in vitro, can associate with
CDK7 in cells, and is activated downstream of PI3K
signaling48,55–58. Transfection of H460 cells with two different
shRNA targeted against PKCι decreased PKCι protein levels by
54.8 ± 3.4% and 52.2 ± 2.8%, phospho-CDK7 levels by 47.1 ±
8.8% and 42.4 ± 3.3%, GLUT1 protein levels by 38.6 ± 3.3% and
37.5 ± 3.0%, and glucose consumption by 33.6 ± 3.5% and 32.9 ±
3.8%, respectively, compared to cells transfected with a control
shRNA (Fig. 7a, b). Transfection of H1975 cells with these same
shRNA yielded better PKCι knockdown (by 76.8 ± 3.8 and 80.7 ±
5.4) but otherwise similar results (Supplementary Fig. 21a, b).
Additionally, PKCι knockdown blocked the ability of Milciclib,
THZ1, and LDC4297 to inhibit glucose consumption in both cell
lines (Fig. 7c, Supplementary Fig. 21c, 22). PKCι knockdown had
no significant effect on the ability of Milciclib to inhibit cell
growth in H460 cells (normalized cell numbers of H460 cells
transfected with control shRNA, expressing one PKCι shRNA
sequence, and expressing a second PKCι shRNA sequence: 73.0 ±
2.2%, 67.5 ± 5.1%, and 76.4 ± 10.5%, respectively). Over-
expression of wild-type CDK7 but not T170A phospho-mutant
CDK7 in H460 cells induced GLUT1 mRNA levels by 55.4 ±
3.5%, GLUT1 protein levels by 50.0 ± 12%, and glucose con-
sumption by 428 ± 37% (Fig. 7d–f). Overexpression of wild-type
and T170A CDK7 in H1975 cells yielded similar results (Sup-
plementary Fig. 23a–c). Overexpression of wild-type CDK7 also
desensitized H460 and H1975 cells to the inhibitory effect of
Milciclib, THZ1, and LDC4297 on glucose consumption but
overexpression of a T170A phospho-site mutant did not (Fig. 7g,
Supplementary Figs. 23 and 24). Overexpression of wild-type
CDK7 in H460 cells also decreased the ability of Milciclib to block
cell growth although this result did not reach statistical sig-
nificance (normalized cell numbers of H460 cells transfected with
control, wild-type CDK7, and T170A CDK7 and treated with
Milciclib: 86.4 ± 9.0%, 101.1 ± 8.7%, and 81.5 ± 7.7%, respec-
tively). These data provide evidence that PKCι regulates the
phosphorylation of CDK7 at Thr170 to promote glucose
consumption.
CDK7 phosphorylation at Thr170 promotes its ability to
phosphorylate the CTD of the Rpb1 subunit of RNA Polymerase
II and regulate multiple transcriptional steps45–47. Milciclib,
THZ1, and LDC4297 all decreased phospho-Ser5 Rpb1 levels in
H460 and H1975 cells (Fig. 7h, Supplementary Figs. 25a and 26).
Milciclib had no effect on phospho-Ser5 Rpb1 levels in A549 and
HCC827 cells (Supplementary Fig. 25b). CDK7 binds to the
GLUT1 promoter in H460 cells (Fig. 7i). Milciclib, THZ1, and
LDC4297 also decreased phospho-Ser5 Rpb1 levels on the
GLUT1 promoter in H460 and H1975 cells (Fig. 7j, Supplemen-
tary Figs. 27 and 28). This suggests that inhibition of CDK7-
dependent Rpb1 phosphorylation may explain the decrease in
GLUT1 mRNA levels.
Collectively, our data support the following model (Fig. 8):
Oncogenic mutant PIK3CA activates the PI3K pathway, leading
to elevated PKCι activity, and increased CDK7 phospho-Thr170
levels. Phospho-CDK7 is activated to phosphorylate Ser5 in the
CTD of the Rpb1 subunit of RNA Polymerase II on the promoter
of various genes, including the GLUT1 gene, leading to increased
GLUT1 mRNA and protein levels, and increased glucose
transport. The interactions between PIK3CA, PKCι, and CDK7
may be direct or indirect and not necessarily linear. Small
molecule inhibitors such as Milciclib, THZ1, and LDC4297 can
interrupt this signaling cascade by inhibiting CDK7, thereby
decreasing Ser5 CTD phosphorylation at the GLUT1 promoter,
leading to decreased GLUT1 mRNA and protein levels, and
decreased glucose transport. Although literature suggests that
phosphoinositide-dependent kinase 1 (PDPK1)48,59,60, a protein
downstream of PIK3CA signaling, phosphorylates PKC isozymes,
it remains possible that PKCι regulates CDK7 independent of
PIK3CA. Additional studies will be required to further evaluate
and develop this model.
Discussion
Despite the clear importance of glucose consumption in health
and disease, identifying new regulators of glucose consumption
remains a slow process. Although some have been identified
through unbiased analyses, most such regulators are discovered
through targeted studies54,61, and currently none of these
approaches are high-throughput. Here, we describe a high-
throughput assay for measuring cellular glucose consumption.
We anticipate that this assay, when coupled to available chemical
or genetic libraries, will enable the unbiased identification of
pathways and proteins that regulate glucose consumption.
We identify that CDK7 inhibition decreases GLUT1 mRNA
levels, GLUT1 protein levels, and glucose transport. Glucose
transport across the cell membrane alone or in combination with
glucose phosphorylation is a major rate-limiting step for glyco-
lysis across multiple systems62. Consistent with this, cancer cells
commonly regulate glucose metabolism by controlling glucose
transport4–7. Our results add additional data to support the
important role for glucose transporters in regulating cancer cell
glucose consumption.
Previous studies suggest various mechanisms through which
enhanced PI3K signaling drives glucose consumption9,63. Here,
we present data to support an alternative mechanism: Mutant
PIK3CA, possibly through the activation of PKCι, activates
CDK7, leading to increased mRNA expression of GLUT1;
increased protein levels of GLUT1; and increased glucose trans-
port. This model suggests various proteins that could potentially
be targeted to limit glucose consumption in cancer cells with
increased PI3K activity. Moreover, the regulation of glucose
consumption by CDK7 provides an additional connection
between cell cycle regulation and cellular metabolism, building on
recent work demonstrating roles for CDK6 and CDK8 in reg-
ulating glucose consumption and glycolysis61,64. These studies
combined with ours suggest that cyclin-dependent kinases may
represent key and potentially targetable cellular nodes that co-
regulate metabolism and cell cycle progression, possibly func-
tioning to ensure that cycling cells have adequate nutrients to
complete cell division.
We screened 3555 drugs against three NSCLC lung cancer cell
lines with different genetic drivers and failed to identify any
drug that decreases glucose consumption in all three cell lines by
> 50%, our threshold for classifying that a small molecule
inhibits glucose consumption. Although this could be due to how
we set this threshold, the data may also suggest that different
genetic drivers use different mechanisms to promote glucose
consumption. Further experiments across additional cell lines
with similar or different engineered or endogenous driver
mutations would be required to make this conclusion. However, if
this conclusion were proven true, it would suggest that the
underlying driver mutations of a patient’s tumor would have to be
known before that patient could be treated with a small molecule
to inhibit glucose consumption in that tumor.
Efforts to target cancer cell metabolism have focused primarily
on identifying direct inhibitors of metabolic enzymes whose
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functions are critical for cancer cell growth and survival65,66.
However, except in rare cases, these same enzymes are present in
healthy tissue throughout the body and most clinical metabolic
inhibitors target only one pathway— nucleotide biosynthesis—
suggesting a potentially unique therapeutic window for directly
inhibiting enzymes in this pathway in cancer65,66. Targeting
glucose consumption with small molecule inhibitors of enzymes
in this pathway has proven challenging17, likely due to a
requirement for glucose in the function of many organ systems.
Here, we show that CDK7 inhibitors block glucose consumption
downstream of an activating PIK3CA mutation and that in mice,
Milciclib does not affect glucose consumption in healthy tissue.
Thus Milciclib may be a more selective inhibitor of glucose
consumption in cancer than other available small molecules.
Because we identify distinct inhibitors of glucose consumption in
genetically different cancer cell lines, we anticipate that the
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efficacy of many of these inhibitors will depend on cancer-specific
genetic alterations and will also be selective for cancer over
healthy cells.
We show that CDK7 overexpression and paradoxically CDK7
knockdown both decrease the sensitivity of H460 and H1975
cells to CDK7 inhibitors. Haploinsufficiency screens in yeast
and mammalian cells to identify targets of cytotoxic drugs
suggest that knockdown of CDK7 should increase the sensi-
tivity of H460 and H1975 cells to the CDK7 inhibitors67. We
cannot explain this paradox. One potential explanation is that
another protein compensates for CDK7 in its absence. Various
other proteins have been identified that can phosphorylate
Rpb1 Ser5, including other cyclin-dependent kinases46,68.
However, CDK7 has been suggested to contribute to multiple
steps of transcription46,69. Which of these steps are necessary
for GLUT1 transcription and which can or cannot be com-
pensated for has yet to be established. An alternative potential
explanation is that CDK7 only regulates glucose consumption
during a certain stage of the cell cycle which CDK7 knockdown
decreases. During CDK7 knockdown, the number of cells in the
specific stage of the cell cycle during which CDK7 regulates
glucose consumption would be decreased and therefore the
ability of CDK7 inhibitors to limit glucose consumption would
be blocked. Additional work will be required to determine
which if any of these explanations holds merit.
We also show that overexpression of the T170A phospho-
mutant CDK7 does not decrease the sensitivity of H460 and
H1975 cells to CDK7 inhibitors. Phosphorylation of CDK7 at
Thr170 stabilizes the TFIIH complex, which phosphorylates RNA
Polymerase II to promote proper transcription of genes47,70. In
our experiments, the TFIIH complexes formed from the CDK7
T170A phospho-mutant are likely less stable than the TFIIH
complexes formed from wild-type CDK7, which may explain why
the CDK7 T170A phospho-mutant has no effect on the ability of
CDK7 inhibitors to alter GLUT1 mRNA levels or glucose con-
sumption. Insofar as CDK7 binds to multiple other proteins to
form the TFIIH complex71, this explanation requires that these
other proteins are expressed at higher levels than CDK7 in the
cells or that CDK7 overexpression induces the expression of these
proteins.
In our high-throughput screen, we treated cells with small
molecules for 24 h before removing the media and measuring
glucose consumption in PBS without drug, so we are unlikely to
have identified small molecules that directly inhibit the proteins
that transport or phosphorylate glucose. Instead the compounds
we identified likely modulate signaling pathways and cellular
processes that either directly or indirectly regulate glucose con-
sumption. However, insofar as our high-throughput assay speci-
fically measures the combined activities of the first two steps in
glucose consumption—glucose transport and phosphorylation—
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we know that every drug we identify decreases the activity of one
or both of these steps.
We show that Milciclib decreases H460 cell xenograft 18F-FDG
consumption, possibly suggesting that decreased tumor 18F-FDG
consumption measured by PET in patients could be used as a
pharmacodynamic biomarker of CDK7 inhibitors. However, we
also show that Milciclib, THZ1, and LDC4297 decrease growth in
HCC827 and A549 cells without inhibiting glucose consumption,
suggesting that in certain genetic backgrounds, CDK7 inhibition
can block cell growth without altering glucose consumption. If
this is the case, a positive change in 18F-FDG consumption fol-
lowing treatment with a CDK7 inhibitor may suggest effective
targeting, but no change in 18F-FDG consumption would have
little predictive value.
Pathological glucose consumption is an important phenotype
in cancer, but there are many diseases in which glucose con-
sumption is affected and in which identifying modulators of
glucose consumption could have value. Thus, we anticipate that
our high-throughput screening assay will have utility across a
variety of cell sources and systems.
Methods
Cell lines. A549 (CCL-185), NCI-H460 (HTB-177), NCI-H1975 (CRL-5908), and
HCC827 (CRL-2868) cells were purchased from ATCC and cultured in RPMI
supplemented with 10% (v/v) FBS, glutamine (4 mM), and penicillin–streptomycin
(100 UmL−1). The cell lines were tested for mycoplasma contamination but were
not authenticated. All cell lines were transduced with a plasmid that expresses
nuclear-localized blue-fluorescent protein (FU-EBFP2-H2B-W; obtained from the
UCLA Molecular Screening Shared Resource (MSSR)).
Drug treatments. Individual drugs were purchased from Sigma-Aldrich, Selleck
Chem, and Cayman Chemical and dissolved in DMSO. Cells were treated with
drugs for 24 h unless otherwise noted. For those experiments that yielded dose
response curves, cells were treated with drugs over the range of concentrations
described in the figures. For those experiments in which only one drug con-
centration was tested, the following drug concentrations were used: Milciclib
(10 µM), THZ1 (10 µM), LDC4297 (10 µM), Buparlisib (1 µM), Erlotinib (200 nM),
and Cytochalasin B (10 µM; added to cells immediately prior to the addition of
2-DG or 3H-2-DG).
2-DG luminescence assay. Following vehicle or drug treatments, 2-DG con-
sumption was measured using the Glucose Uptake-Glo kit (Promega Corporation)
per the manufacturer’s protocol.
3H-2-DG consumption. Following vehicle or drug treatments, media was removed
from cells, and the cells were washed (3×; 1× PBS). 3H-2-DG (1.25 mM, 5 µCi in 1x
PBS) was added to the cells and the cells were incubated (30 min; 37 °C). The cells
were washed (3×; cold 1× PBS), lysed in RIPA buffer, the lysate was added to
scintillation fluid, and the radioactivity was measured on a scintillation counter. 2-
DG accumulation was normalized to cell numbers.
Compound libraries. The Selleck Chemicals kinase inhibitor library, the Prestwick
FDA-approved drug library, the LOPAC collection, and the NIH clinical collection
small molecule library were prepared and maintained by the UCLA MSSR.
High-throughput 2-DG luminescence assay. A small molecule compound (1 mM
in DMSO; 0.5 µL) or DMSO (0.5 µL) was pinned into 25 µL of growth media in
wells of a 384-well plate and cells (0.26 × 106 cells mL−1 in 25 µL of growth media)
were dispensed into these wells using a Multidrop dispenser. The plates were
incubated for 24 h at 37 °C, 5% CO2. After the 24 h incubation, the plates were
washed (1x PBS containing 0.25% (w/v) BSA; 3×; 80 µL) and 2-DG (1.25 mM in 1×
PBS containing 0.25% (w/v) BSA; 20 µL) was added using a BioTek EL406
Microplate washer/dispenser. The fluorescence in each well of the 384-well plate
was imaged using an Image Express XL (10 min; 37 °C) and the plates were further
incubated (10 min; 37 °C). Stop buffer (0.4 N HCl containing 2% (w/v) dodecyl-
trimethylammonium bromide; 6 µL) was added using the BioTek EL406 Micro-
plate washer/dispenser, the plates were spun (2200 rpm; 1 min), shaken (900 rpm,
1 min), and spun again (2200 rpm, 1 min), and detection reagent (Glucose Uptake-
Glo kit detection reagent diluted 1:1 in 1M tris base; 40 µL) was added using a
Multidrop dispenser. The plates were incubated at room temperature for 1 h, after
which luminescence per well was measured on a PerkinElmer EnVision plate
reader. For each well, luminescence was normalized to total cell numbers (deter-
mined from the fluorescent microscope image), and values for individual wells
were normalized to the DMSO control for that row. Cytochalasin B (10 µM) was
added to designated wells immediately prior to the addition of 2-DG. Control
experiments in which 2-DG was not added were performed exactly the same except
that 1× PBS without 2-DG was used in place of the 1X PBS with 2-DG (please see
also Supplementary Table 2).
Those small molecules that inhibited glucose consumption by > 50% were
rescreened in duplicate, and any small molecule that inhibited glucose
consumption by > 3 standard deviations from the mean in this experiment was
considered a validated inhibitor of glucose consumption.
Cell growth. BFP+ cells were counted during the 2-DG luminescence assay using
an Image Express XL. Normalized cell numbers were calculated as the ratio
between the number of cells in wells treated with 10 μM Milciclib and the number
of cells in wells treated with DMSO and reported as a percentage.
Measurements of glucose and lactate media concentrations. Cells were incu-
bated in media containing DMSO or Milciclib (10 μM) for 20 h, after which the
media was changed into freshly prepared RPMI containing DMSO or Milciclib
(10 μM). Four hours later, media (1 mL) was collected and analyzed, thus allowing
us to measure media glucose consumption from 20 to 24 h post-Milciclib treat-
ment. Glucose and lactate concentrations in the media were measured using a
Bioprofile Basic Analyzer per the manufacturer’s protocol.
18F-FDG PET. H460 xenografts were implanted into the subcutaneous space of
NOD scid gamma mice. When the tumors had reached ~0.05 cm3, mice were fasted
overnight, anesthetized, 18F-FDG (~3MBq) was injected through the tail vein, and
one hour later the mice were imaged on a G8 PET/CT. Mice were treated with
Milciclib (30 mg kg−1 in 0.5% carboxymethylcellulose; PO; BID) or vehicle (0.5%
carboxymethylcellulose; PO; BID), and 24 h after the first treatment, imaged again
with 18F-FDG PET. Analyses were conducted in the AMIDE software. Three-
dimensional regions of interest (ROI) were drawn around the tumor and the mouse
to measure total tumor activity and total injected dose, respectively, and these
values were used to calculate the percent injected dose per cubic centimeter (%ID/
cc) in the tumor. All mouse experiments complied with relevant ethical guidelines
and were approved by the UCLA Animal Research Committee.
qRT-PCR. RNA was isolated from H460 cells, 20 and 24 h after treatment with
DMSO or Milciclib (10 μM) or 16 h after treatment with Deferoxamine (100 μM)
using the GeneJET RNA purification kit (Thermo Fisher) per the manufacturer’s
protocol. Reverse transcription and quantitative real-time PCR was conducted
using ProtoScript II First Strand cDNA Synthesis Kit (New England BioLabs) and
PowerUp SYBR Green Master Mix (Thermo Fisher), respectively, following the
manufacturer’s protocol and using the following primers:
GLUT1 (SLC2A1) forward primer: GATTGGCTCCTTCTCTGTGG
GLUT1 (SLC2A1) reverse primer: TCAAAGGACTTGCCCAGTTT
GLUT3 (SLC2A3) forward primer: GTCTGAAGAGCTATGGCCGC
GLUT3 (SLC2A3) reverse primer: AACCGCTGGAGGATCTGCTT
Hexokinase 1 forward primer: GGACTGGACCGTCTGAATGT
Hexokinase 1 reverse primer: ACAGTTCCTTCACCGTCTGG
Hexokinase 2 forward primer: CAAAGTGACAGTGGGTGTGG
Hexokinase 2 reverse primer: GCCAGGTCCTTCACTGTCTC
Ceruloplasmin forward primer: CCCTGGAGAATGGATGCTCA
Ceruloplasmin reverse primer:CTAACATGCTTCCCACGGATATT
SERPINE1 forward primer: CACAAATCAGACGGCAGCACT
SERPINE1 reverse primer: CATCGGGCGTGGTGAACTC
VEGFA forward primer: AGGAGGAGGGCAGAATCATCA
VEGFA reverse primer: CTCGATTGGATGGCAGTAGCT
MAPK forward primer: CCTCAAGCCTTCCAACCTG
MAPK reverse primer: ATAATTTCTGGAGCCCTGTACC
All mRNA levels were normalized to MAPK mRNA levels.
Immunoblots. Cell lysates from H460, A549, H1975, and HCC827 cells were
prepared 24 h after treatment with DMSO, Milciclib (1 or 10 μM), THZ1 (10 μM),
or LDC4297 (10 μM); 16 h after treatment with 1× PBS or Deferoxamine (100 μM);
or 72 h after transfection with shRNA or an overexpression plasmid. Uncropped
immunoblots are presented in Supplementary Fig. 29.
The following antibodies were used: HIF-1α (Novus Biologicals; NB100-105;
1:1000 dilution), GLUT1 (Millipore Sigma; 07-1401; 1:500 dilution), GLUT3
(Abcam; ab15311; 1:1000 dilution), Hexokinase 1 (Cell Signaling; C35C4; 1:1000
dilution), Hexokinase 2 (Cell Signaling; C64G5; 1:1000 dilution), CDK2 (Cell
Signaling; 78B2; 1:1000 dilution), CDK4 (Cell Signaling; D9G3E; 1:1000 dilution),
CDK7 (Cell Signaling; MO1; 1:1000 dilution), TRKA (Cell Signaling; 12G8; 1:1000
dilution), PIK3CA (Cell Signaling; C73F8; 1:1000 dilution), PTEN (Cell Signaling;
9559; 1:1000 dilution), Phospho-T170 CDK7 (Abcam; ab155976; 1:1000 dilution),
Rpb1 NTD (Cell Signaling; D8L4Y; 1:1000 dilution), Phospho-S5 Rpb1 (Cell
Signaling; D9N5I; 1:1000 dilution), PKCι (BD Biosciences; Clone 23; 1:1000
dilution), TXNIP (Cell Signaling; D5F3E; 1:1000 dilution), and Beta Actin
(Imgenex; IMG-5142; 1:1000 dilution). Immunoblots were analyzed using an
Odyssey Imaging System (LI-COR).
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FRET. H460 cells were transfected with the FLIPglu-700 FRET construct36–38 using
Fugene HD per the manufacturer’s protocol. Two days post-transfection, FRET
studies were performed 24 h after treatment with DMSO or Milciclib (10 μM) by
monitoring emissions from the yellow fluorescent protein (YFP) and the cyan
fluorescent protein (CFP) (535/40 and 480/30 nm wavelengths, respectively; signal
separated by a 505 nm long-pass dichroic filter) in cells exposed to light at a
wavelength that excites CFP (436/20b nm wavelength). Cells in 1X PBS were
treated with glucose (10 mM) with or without Cytochalasin B (10 µM). Results
were analyzed by plotting the ratio of the YFP and CFP signal and fitting this to an
exponential decay curve.
Plasmid overexpression. H460, HCC827, and H1975 cells were plated into wells
of a six-well plate and transfected with control YFP, GLUT1, GLUT3, PTEN-GFP,
PIK3CA, or HA-CDK7 plasmids using Fugene HD per the manufacturer’s pro-
tocol. Two days later, the cells were transferred to wells of a 384-well plate con-
taining defined concentrations of the different inhibitors. Glucose consumption
was measured 24 h later per the high-throughput method described above. The
PIK3CA overexpression plasmid was a gift from Jean Zhao (Addgene plasmid
#12522). The PTEN-GFP plasmid was a gift from Alonzo Ross (Addgene plasmid
#13039). The HA-CDK7 plasmid was a gift from Matija Peterlin (Addgene
plasmid # 14647). The GLUT and YFP plasmids were a gift from the Nathanson
Lab (UCLA).
Mutagenesis. The CDK7 T170A mutant was prepared using a Q5 Site-Directed
Mutagenesis kit (New England BioLabs) according to the manufacturer’s protocol
and using the following primers:
CDK7 T170A forward primer: TAGAGCTTATgcaCATCAGGTTG
CDK7 T170A reverse primer: TTGGGGCTCCCAAAAGAT
shRNA and siRNA. Control shRNA, pooled shRNA, and individual shRNA
constructs were obtained from the MSSR or Sigma Aldrich. Control siRNA and
CDK7 siRNA were obtained from Dharmacon. H460 and H1975 cells were
transfected with shRNA constructs and siRNA sequences using Fugene HD per the
manufacturer’s protocol. Two days later, the cells were plated into wells of a 384-
well plate containing various concentrations on each different inhibitor and 24 h
later, glucose consumption was measured in high-throughput as described above.
Chromatin immunoprecipitation (ChIP). ChIP was performed on H460 cells
transfected with a control YFP or CDK7 HA construct, or on H460 and H1975
cells 6 h after treatment with DMSO, Milciclib, THZ1, or LDC4297 (10 μM) using
the SimpleChIP Plus ChIP kit (Cell Signaling) following the manufacturer’s pro-
tocol. The following antibodies were used: HA (Abcam; ab9110; 1:714 dilution),
Rpb1 NTD (Cell Signaling; D8L4Y; 1:147 dilution), and phospho-Ser5 Rpb1 CTD
(Cell Signaling; D9N5I; 1:50 dilution). qPCR was performed as previously descri-
bed using the following primers:
GLUT1 (SLC2A1) forward primer: CCCTAGTGCACCGAAGTCAC
GLUT1 (SLC2A1) reverse primer: GTACCCGGCTGTAAGGCAAG
Data analysis. All data are normalized to control knockdown, overexpression, or
vehicle-treated cells except for the dose response curves. For the dose response
curves, data is normalized to vehicle-treated cells for each genotype. Data were
plotted, IC50 values were calculated, and statistics were performed using Graphpad
Prism 7. All data are plotted as mean ± SEM.
Statistical analyses. Pairwise two-sided t tests, and one-way and two-way
ANOVA analyses with multiple comparison tests were performed. In all experi-
ments except for the 18F-FDG PET experiment, measurements were made from
distinct samples. In the 18F-FDG PET experiment, measurements were made on
the same xenografts, before and after treating the mice with vehicle or Milciclib.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data is available in the Article, Supplementary Information, or from the authors
upon reasonable request.
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